Results 211 to 220 of about 3,220,825 (277)

Dissolving porcine and human microthrombi by short exposure to microdoses of alteplase in an in vitro model of microvascular obstruction. [PDF]

Sci Rep
Milusev A, Rösch Y, Kuster Y, Wolint P, Ulmer J, Weisskopf M, Cesarovic N, Obrist D.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pharmacokinetics and Pharmacodynamics of Fibrinolytic Agents

2015
In this chapter, the historical development, as well as, pharmacokinetics and pharmacological properties of the more frequently used fibrinolytic agents in pulmonary embolism patients, namely streptokinase, alteplase, and tenecteplase are analyzed. The historical development of the first-, second-, and third-generation fibrinolytics has been reviewed ...
H. David Rodriguez, Carlos Jerjes-Sánchez   +1 more
openaire   +3 more sources

Development of New Fibrinolytic Agents

Current Pharmaceutical Design, 2006
Since the activation of coagulation system and platelets triggers the thrombosis, the agents possessing anticoagulation or anti-platelet function have been used for the antithrombotic procession actions. However, in the physiological condition, the fibrinolytic system serves as antithrombotic, which removes the thrombus from the circulation.
Shigeru Ueshima, Osamu Matsuo
openaire   +3 more sources

Fibrinolytic Agents: Mechanisms of Activity and Pharmacology

Thrombosis and Haemostasis, 1995
Fibrinolytic (thrombolytic) agents activate the fibrinolytic system by conversion of the inactive proenzyme, plasminogen into the active enzyme plasmin, that degrades fibrin. Agents available for clinical use are: the physiologic tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA)--either in a single chain (scu-PA ...
D. Collen, H.R. Lijnen
openaire   +3 more sources

Fibrinolytic agents in the treatment of intraventricular hemorrhage in adults [PDF]

Critical Reviews in Neurosurgery, 1998
This paper aims to review current literature on the treatment of acute intraventricular hemorrhage in adults with intraventricular infusion of fibrinolytic agents. A literature search on the topics of "intraventricular hemorrhage" or "intracerebral hemorrhage" with "thrombolytic therapy", "fibrinolytic therapy", "urokinase", "streptokinase", "tissue ...
Stephen J. Haines, Marc Lapointe
openaire   +3 more sources

Synthetic fibrinolytic agents

Progress in Cardiovascular Diseases, 1979
W ITHOUT question, degenerative vascular disease remains the major cause of death and morbidity in the Western world. In the United Kingdom, cardiovascular disease is responsible for about 50% of all deaths in men aged 45-54 yr, and this must be compared with only 25% of deaths in this age group resulting from cancers.’ Although little direct proof ...
J. F. Davidson, Isobel D. Walker
openaire   +3 more sources

Fibrinolytic agents for peripheral arterial occlusion.

Cochrane Database of Systematic Reviews, 2010
BACKGROUND Peripheral arterial thrombolysis is used in the management of peripheral arterial ischaemia. Streptokinase was originally used but safety concerns led to a search for other agents. Urokinase and recombinant tissue plasminogen activator (rt-PA)
I. Robertson, D. Kessel, D. Berridge
semanticscholar   +1 more source

The clinical use of fibrinolytic agents

The American Journal of Surgery, 1977
Two fibrinolytic drugs, streptokinase and urokinase, have undergone extensive clinical evaluation in the past fifteen years. Current evidence suggests that these agents may become the drugs of choice in the treatment of certain patients with venous thrombosis and pulmonary embolism.
John M. Porter, Scott H. Goodnight
openaire   +3 more sources

Fibrinolytic Agents in the Treatment of Necrobiosis Lipoidica

Angiology, 1976
E. .. Rhodes
openaire   +6 more sources